title: [Porphyria cutanea tarda, hemodialysis and HCV hepatopathy].
abstract: Porphyria cutanea tarda is treated with phlebotomies in the absence of renal failure. However, in patients on maintenance hemodialysis, this will lead to the need for high doses of erythropoietin. We describe the case of a 63-year-old hemodialysis patient who had chronic hepatitis C virus and developed porphyria cutanea tarda after iron overload due to repeated transfusions. She was treated with erythropoietin and phlebotomies reaching clinical remission 4 months after beginning treatment.
authors.affiliation: Servicio de Nefrología, Hospital Universitari Arnau de Vilanova de Lleida, Rovira Roure, 80 25198 Lleida.
authors.forename: S
authors.initials: S
authors.lastname: Muray
authors.forename: J M
authors.initials: JM
authors.lastname: Casanova
authors.forename: M P
authors.initials: MP
authors.lastname: Marco
authors.forename: L
authors.initials: L
authors.lastname: Craver
authors.forename: M
authors.initials: M
authors.lastname: Martín
authors.forename: E
authors.initials: E
authors.lastname: Fernández
mesh_terms: D004921:Erythropoietin / Q000627:therapeutic use; D005260:Female; D016174:Hepacivirus / Q000302:isolation & purification; D019698:Hepatitis C, Chronic / Q000150:complications*; D006801:Humans; D019190:Iron Overload / Q000150:complications* / Q000628:therapy; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000628:therapy; D008875:Middle Aged; D017119:Porphyria Cutanea Tarda / Q000209:etiology* / Q000628:therapy; D006435:Renal Dialysis
chemical_list: D004921:Erythropoietin